- Home
- IMCC vs APVO Comparison
IMCC vs APVO Comparison
Compare IMCC & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCC
- APVO
- Stock Information
- Founded
- IMCC 1980
- APVO 2016
- Country
- IMCC Israel
- APVO United States
- Employees
- IMCC N/A
- APVO N/A
- Industry
- IMCC Medicinal Chemicals and Botanical Products
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- IMCC Health Care
- APVO Health Care
- Exchange
- IMCC Nasdaq
- APVO Nasdaq
- Market Cap
- IMCC 10.0M
- APVO 4.1M
- IPO Year
- IMCC N/A
- APVO N/A
- Fundamental
- Price
- IMCC $3.37
- APVO $3.19
- Analyst Decision
- IMCC
- APVO Strong Buy
- Analyst Count
- IMCC 0
- APVO 1
- Target Price
- IMCC N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- IMCC 146.8K
- APVO 6.7M
- Earning Date
- IMCC 08-13-2025
- APVO 08-07-2025
- Dividend Yield
- IMCC N/A
- APVO N/A
- EPS Growth
- IMCC N/A
- APVO N/A
- EPS
- IMCC N/A
- APVO N/A
- Revenue
- IMCC $37,894,737.00
- APVO N/A
- Revenue This Year
- IMCC $47.12
- APVO N/A
- Revenue Next Year
- IMCC $12.83
- APVO N/A
- P/E Ratio
- IMCC N/A
- APVO N/A
- Revenue Growth
- IMCC 12.68
- APVO N/A
- 52 Week Low
- IMCC $1.29
- APVO $2.81
- 52 Week High
- IMCC $7.12
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- IMCC 60.91
- APVO 36.72
- Support Level
- IMCC $2.37
- APVO $2.89
- Resistance Level
- IMCC $3.50
- APVO $3.19
- Average True Range (ATR)
- IMCC 0.38
- APVO 0.93
- MACD
- IMCC 0.05
- APVO 0.25
- Stochastic Oscillator
- IMCC 84.73
- APVO 2.95
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.